TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34287970
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg apraglutide
Study: 34287970
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg apraglutide
Study: 34414672
Drug: Enpatoran 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enpatoran 1, 3, 9, 25, 50, 100, or 200 mg single dose
Study: 34414672
Drug: Enpatoran 9,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enpatoran 9, 25, or 200 mg once daily for 14 days
Study: 34414672
Drug: Enpatoran 25
Normalized name: Enpatoran
DrugBank: Enpatoran (DB16501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enpatoran 25 or 50 mg twice daily for 14 days
Study: 34414672
Drug: Enpatoran 25
Normalized name: Enpatoran
DrugBank: Enpatoran (DB16501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enpatoran 25 mg single dose with food
Study: 34414672
Drug: Enpatoran 200
Normalized name: Enpatoran
DrugBank: Enpatoran (DB16501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enpatoran 200 mg single dose
Study: 32942788
Drug: Triamcinolone acetate
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetate (TA) 40 mg
Study: 32942788
Drug: Triamcinolone acetate
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetate (TA) 20 mg
Study: 34321056
Drug: Tuina with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuina with herbal ointment
Study: 34321056
Drug: Herbal ointment
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal ointment (control group)
Study: 33730928
Drug: 0.1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 μg/kg
Study: 33730928
Drug: 0.3 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 μg/kg
Study: 33730928
Drug: 0.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg/kg
Study: 33730928
Drug: 1.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg/kg
Study: 35380356
Drug: 18 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g/day of MCT oil
Study: 34445834
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (400 mg/d)
Study: 34445834
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group, average calcium intake 400 mg/d)
Study: 35460145
Drug: Jujube syrup,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jujube syrup, consumed twice a day for 8 weeks
Study: 35460145
Drug: Placebo, consumed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, consumed twice a day for 8 weeks
Study: 33183463
Drug: Nanoparticle-loaded edaravone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanoparticle-loaded edaravone treatment (NET)
Study: 33183463
Drug: Edaravone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone treatment (ET)
Study: 33094682
Drug: meloxicam IV
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: meloxicam IV 30 mg
Study: 32726514
Drug: Subcutaneous sarilumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous sarilumab (150 or 200 mg)
Study: 32726514
Drug: Intravenous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous tocilizumab (4 or 8 mg/kg)
Study: 32726514
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (sarilumab and tocilizumab)
Study: 34158245
Drug: Sunitinib 25
Normalized name: sunitinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 25 mg PO daily with paclitaxel 80 mg/m2 IV weekly ×12 followed by doxorubicin 24 mg/m2 IV weekly + cyclophosphamide 60 mg/m2 PO daily with G-CSF support
Study: 34452959
Drug: High fibre
Normalized name: Adult high protein high fibre formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fibre supplement (resistant starch)
Study: 32796391
Drug: Anti-inflammatory combination
Normalized name: ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory combination therapy
Study: 32216832
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) combined with bright light therapy (BLT) - one face-to-face session on sleep strategies, one telephone call, seven email packages, and wearing Luminette® light glasses for 20 minutes each morning for 6 weeks.
Study: 32216832
Drug: Relaxation audio-enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation audio-enhanced treatment as usual (TAU+) - two relaxation audio tracks via email.
Study: 36060925
Drug: Crocin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin (30 mg tablets, three consecutive doses, 1 day before to 1 day after CM exposure)
Study: 36060925
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard hydration therapy only)
Study: 36214036
Drug: Home delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home delivery of chronic medication
Study: 33788457
Drug: Electrothermal acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrothermal acupuncture therapy applied at Guanyuan (CV 4), Qihai (CV 6), Zusanli (ST 36), Hegu (LI 4), Sanyinjiao (SP 6), 30 min each treatment, once a day for 5 days
Study: 33788457
Drug: Opioid painkillers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid painkillers (oxycodone hydrochloride prolonged-release tablet or morphine sulfate sustained-release tablet)
Study: 35311718
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (MT) 5 times a week for 30 minutes each time over a period of 3 weeks
Study: 35311718
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CT) receiving medication and routine rehabilitation training
Study: 32949864
Drug: Targeted treatment
Normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted treatment (TT) with fenbendazole at 22, 27 and 36 weeks post‐placement (WPP)
Study: 32949864
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (CT) at 27 WPP
Study: 35476239
Drug: Dynamic real-time
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dynamic real-time feedback via daily computer-generated email to providers regarding their HCAHPS performance and peer comparison.
Study: 35398397
Drug: Internet- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet- and mobile-based intervention (IMI) + treatment as usual (TAU)
Study: 33560104
Drug: Bilateral lower
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral lower extremity DUS surveillance on days 1, 3, and 7 and weekly during hospitalization (US)
Study: 33217877
Drug: Oral Jianweixiaoshi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Jianweixiaoshi tablets
Study: 34907021
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (25 mg/kg body weight per day) for 12 months
Study: 33885203
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (21 mg once daily with taper)
Study: 32310273
Drug: Pitavastatin therapy
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin therapy in PWH
Study: 32310273
Drug: Pitavastatin therapy
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin therapy in non-HIV participants
Study: 35422024
Drug: Bisoprolol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (1.25 mg tablets, titrated up to a maximum of 5 mg daily over 4-7 weeks)
Study: 34275697
Drug: De-escalation therapy
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalation therapy
Study: 34275697
Drug: De-escalation to
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalation to clopidogrel or low-dose prasugrel
Study: 33509043
Drug: St. Thomas
Normalized name: St. Thomas lidpod
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. Thomas solution
Study: 32350749
Drug: Cannabidiol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol (20 mg/kg/day)
Study: 32966832
Drug: Sonodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonodynamic therapy (SDT)
Study: 35561480
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate (30 mg/day elemental zinc)
Study: 35918587
Drug: Oniria® (1.98
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oniria® (1.98 mg prolonged-release melatonin)
Study: 35918587
Drug: Immediate-release tablets
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tablets (IRT)
Study: 34163127
Drug: ISVCZ 50ug/0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISVCZ 50ug/0.1 mL
Study: 34163127
Drug: ISAMB 5ug/0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISAMB 5ug/0.1 mL
Study: 34163127
Drug: ISNTM 10ug/0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISNTM 10ug/0.1 mL
Study: 34752681
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) with maintenance antidepressant medication (mADM)
Study: 34752681
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) with discontinued maintenance antidepressant medication (mADM)
Study: 34752681
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) with continued maintenance antidepressant medication (mADM)
Study: 33757137
Drug: Increased nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased nasal flow therapy (8-10 L/min)
Study: 33757137
Drug: Standard nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nasal flow therapy (5-7 L/min)
Study: 35030133
Drug: Intraoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intravenous bolus dose of Dexmedetomidine
Study: 36193094
Drug: L. crispatus
Normalized name: L. crispatus,gasseri,jensenii,rhamnosus/B. infantis 6 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. crispatus G14‐5M (2 g twice daily for one month)
Study: 36193094
Drug: L. helveticus
Normalized name: L. helveticus,rhamnosus/B. longum/zinc yeast/selenium yeast 2 billion cell-2 mg-12.5 mcg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. helveticus M2‐09‐R02‐S146 (2 g twice daily for one month)
Study: 36193094
Drug: L. plantarum
Normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. plantarum CCFM8610 (2 g twice daily for one month)
Study: 33341950
Drug: Health information
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health information via a tablet computer plus 10 live health coaching sessions delivered virtually (intervention group; n=125)
Study: 33341950
Drug: Health information
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health information via a tablet only (control group; n=125)
Study: 36447142
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) injected on embryo transfer day
Study: 32498771
Drug: Tablet-based control
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based control intervention with comparable audio, visual, and tactile components
Study: 35576073
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg once daily for 3 months or until stone free
Study: 35576073
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 3 months or until stone free
Study: 33954805
Drug: Ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1 mg/kg)
Study: 34715934
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day ergothioneine for 12 weeks
Study: 34715934
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day ergothioneine for 12 weeks
Study: 32726103
Drug: Iron-oxide containing
Normalized name: IRON OXIDES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-oxide containing formulations
Study: 32086888
Drug: Zhuyuan soup
Normalized name: MALT SOUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhuyuan soup combined with fumigation and oral administration
Study: 32086888
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal spray (western medicine group)
Study: 32511534
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no inhalation of NO)
Study: 33861194
Drug: Adrenaline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline (1 mg)
Study: 36063792
Drug: Goal-directed care
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed care bundle of intensive blood pressure lowering, glycemic control, antipyrexia, and anticoagulation reversal treatment
Study: 32981468
Drug: Concurrent complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent complex training (CPX)
Study: 32270496
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL crystalloid fluid bolus over 30 minutes
Study: 616593029
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive behavioral therapy (ICBT) program
Study: 32334602
Drug: Benzodiazepines or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines or z-hypnotics dispensed
Study: 32334602
Drug: Mean daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean daily dose of benzodiazepines or z-hypnotics
Study: 32334602
Drug: Mean daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean daily dose of pregabalin
Study: 32334602
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of gabapentinoids with benzodiazepines or z-hypnotics
Study: 32334602
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of non-OAT opioids with benzodiazepines or z-hypnotics
Study: 35998897
Drug: Calanus oil
Normalized name: CALANUS OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calanus oil (2 g/day)
Study: 34700446
Drug: High-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose treatment arm (74 Gy)
Study: 34700446
Drug: Low-dose treatment
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose treatment arm (60 Gy)
Study: 34700446
Drug: Dose to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose to cardiac sub-regions
Study: 34700446
Drug: Mean lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean lung dose
Study: 34223605
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy for 52 weeks
Study: 32638173
Drug: Systemic enzyme
Normalized name: alpha-D-galactosidase enzyme Chewable Tablet [Beano]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic enzyme therapy (SET) administered 48 hours prior to surgery
Study: 32638173
Drug: Systemic enzyme
Normalized name: alpha-D-galactosidase enzyme Chewable Tablet [Beano]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic enzyme therapy (SET) started on the day of surgery
Study: 32638173
Drug: Systemic enzyme
Normalized name: alpha-D-galactosidase enzyme Chewable Tablet [Beano]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic enzyme therapy (SET) started immediately after surgery
Study: 36447152
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with paclitaxel/cisplatin/5‐fluorouracil (TPF) followed by concurrent chemoradiotherapy (CCRT)
Study: 32702334
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily for 6 months
Study: 34514635
Drug: First line
Normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line treatment according to national guidelines
Study: 34514635
Drug: New and
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 27 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 50 mg in 1 mL TOPICAL LOTION [Loreal Paris Age Perfect Rosy Tone SPF 30 Renew and revive healthy tone Visibly younger-looking skin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New and better treatments introduced
Study: 34712863
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg daily for 42 days)
Study: 36458825
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg)
Study: 32167550
Drug: Ultrasound-guided glossopharyngeal
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided glossopharyngeal nerve block (UGPNB) with 1.5 mL of 0.5% ropivacaine and 20 mg of methylprednisolone
Study: 36091794
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g LSZ capsules three times a day for 90 days
Study: 36091794
Drug: Placebo LSZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo LSZ capsules for 90 days
Study: 35180283
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (medication advice, rehabilitation exercise, nurse follow-up)
Study: 35067660
Drug: 1-drop regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-drop regimen of intracameral delivery of moxifloxacin and dexamethasone suspension and topical bromfenac for 30 days
Study: 35067660
Drug: 3-drop regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-drop regimen of topical moxifloxacin 0.5% 4 times a day for 7 days, bromfenac 0.07% daily for 30 days, and prednisolone acetate 1% 4 times a day for 30 days
Study: 36106312
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.3% ropivacaine (Group L)
Study: 36106312
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.5% ropivacaine (Group H)
Study: 34444999
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (CG) - maintained their daily routine
Study: 33596494
Drug: Ayurvedic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic treatment regime (1 g Giloy Ghanvati, 2 g Swasari Ras, 0.5 g Ashwagandha, 0.5 g Tulsi Ghanvati, and 4 drops of Anu taila)
Study: 33596494
Drug: Placebo (identical-looking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical-looking tablets and drops)
Study: 34695064
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) 150 mg/kg
Study: 35559241
Drug: Probiotic supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplements
Study: 33585896
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 × 150 mg/day)
Study: 33585896
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 × 150 mg/day)
Study: 32069044
Drug: Compounds with
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compounds with the lowest 130 reorganization energy
Study: 34774538
Drug: Carboxymethylcellulose (CMC)
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxymethylcellulose (CMC) 15 g per day
Study: 34537057
Drug: Abatacept 125
Normalized name: abatacept 125 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept 125 mg weekly
Study: 33705695
Drug: Secondary cytoreduction
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary cytoreduction followed by chemotherapy (six 3-weekly cycles of intravenous paclitaxel [175 mg/m2] or docetaxel [75 mg/m2] combined with intravenous carboplatin [AUC 5 mg/mL per min])
Study: 33705695
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (no surgery group)
Study: 33705695
Drug: Secondary cytoreduction
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary cytoreduction followed by chemotherapy
Study: 36318025
Drug: Amoxicillin with
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin with clavulanate for one week before surgery
Study: 33514447
Drug: Brief problem
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief problem solving therapy (PST) delivered in four sessions over a maximum period of eight weeks
Study: 33514447
Drug: Brief problem
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief problem solving therapy (PST)
Study: 32214298
Drug: Nebulized ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized ketamine 3 mg/kg
Study: 34582670
Drug: CCRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCRT with weekly cisplatin followed by observation (arm A)
Study: 33034099
Drug: Althaea officinalis
Normalized name: Althaea officinalis root
DrugBank: Althea root (DB13525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Althaea officinalis 1% ointment
Study: 32347684
Drug: Guidance document
Normalized name: ZINC OXIDE 120 mg in 1 mL TOPICAL CREAM [GUIDANCE TO GLOW TRU SPF 35]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guidance document recommendations on diagnosis and treatment of LGG patients